Gornet MF, Lanman TH, Burkus JK, et al. - A multicenter, prospective, randomized, controlled, FDA-approved clinical trial was conducted to compare narcotic medication use between cervical disc arthroplasty (CDA) with the Prestige LP disc and anterior cervical discectomy and fusion (ACDF) at two levels. Researchers randomized a total of 397 individuals having 2-level intractable cervical radiculopathy and/or myelopathy to receive CDA (n=209) or ACDF (n=188) in an FDA-regulated clinical trial. The results of this study demonstrate that percentage of subjects who used opioid medications once or more a day after receiving the Prestige LP CDA was statistically lower than that in the ACDF group overall and at most postoperative time points. For CDA patients, the greater clinical outcome improvements shown in the clinical trial may have led to less use of narcotic medications. For further studies, after surgery, the use of narcotics might be considered as a treatment outcome in addition to patient-reported functional and pain outcomes.